Innovative Radiotherapeutics: Lutetium-177 FAPI-04 used therapeutically in Cancer Treatment and Fibroblast Activation Protein Inhibitors (FAPI): A New Frontier in Cancer Diagnosis and Therapy
Innovative Radiotherapeutics: Lutetium-177 FAPI-04 used therapeutically in Cancer Treatment and Fibroblast Activation Protein Inhibitors (FAPI): A New Frontier in Cancer Diagnosis and Therapy Summary: Lutetium-177 FAPI-04, a therapeutic analogue of the PET imaging agent 68Ga-FAPI-04, has emerged as a promising radiotherapeutic targeting cancer-associated fibroblasts (CAFs). This novel agent, part of the Fibroblast Activation Protein (FAP)-specific inhibitor family, offers significant potential in oncology and beyond, with early preclinical and clinical data demonstrating its efficacy in imaging and treatment. This article explores the development, mechanism, and clinical applications of Lutetium-177 FAPI-04 and its counterparts. Keywords: 177Lu-FAPI-04; Cancer-associated fibroblasts; FAP-specific inhibitors; Radiotherapeutics; PET imaging; 68Ga-FAPI-04. Fibroblast activation protein inhibitors (FAPI) are emerging as promising oncology tools for diagnosing and treating variou...
